- Home
- MGEE vs FOLD Comparison
MGEE vs FOLD Comparison
Compare MGEE & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGEE
- FOLD
- Stock Information
- Founded
- MGEE 1855
- FOLD 2002
- Country
- MGEE United States
- FOLD United States
- Employees
- MGEE N/A
- FOLD N/A
- Industry
- MGEE Electric Utilities: Central
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- MGEE Energy
- FOLD Health Care
- Exchange
- MGEE Nasdaq
- FOLD Nasdaq
- Market Cap
- MGEE 3.0B
- FOLD 2.5B
- IPO Year
- MGEE N/A
- FOLD 2007
- Fundamental
- Price
- MGEE $83.13
- FOLD $8.15
- Analyst Decision
- MGEE Sell
- FOLD Strong Buy
- Analyst Count
- MGEE 2
- FOLD 9
- Target Price
- MGEE $79.00
- FOLD $26.44
- AVG Volume (30 Days)
- MGEE 146.7K
- FOLD 5.8M
- Earning Date
- MGEE 11-05-2025
- FOLD 11-05-2025
- Dividend Yield
- MGEE 2.15%
- FOLD N/A
- EPS Growth
- MGEE 12.86
- FOLD N/A
- EPS
- MGEE 3.60
- FOLD N/A
- Revenue
- MGEE $701,317,000.00
- FOLD $571,160,000.00
- Revenue This Year
- MGEE $10.77
- FOLD $20.98
- Revenue Next Year
- MGEE $3.48
- FOLD $20.74
- P/E Ratio
- MGEE $23.22
- FOLD N/A
- Revenue Growth
- MGEE 8.61
- FOLD 25.35
- 52 Week Low
- MGEE $81.14
- FOLD $5.51
- 52 Week High
- MGEE $109.22
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- MGEE 46.63
- FOLD 56.40
- Support Level
- MGEE $81.14
- FOLD $7.69
- Resistance Level
- MGEE $83.38
- FOLD $8.59
- Average True Range (ATR)
- MGEE 1.43
- FOLD 0.37
- MACD
- MGEE -0.05
- FOLD -0.05
- Stochastic Oscillator
- MGEE 59.39
- FOLD 54.44
About MGEE MGE Energy Inc
MGE Energy provides electric service to 161,000 customers and natural gas service to 173,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.